Descripción del proyecto
Tecnología innovadora para la estratificación tumoral en pacientes con cáncer de pulmón
El cáncer de pulmón es la principal causa de muerte entre los enfermos de cáncer en todo el mundo. Los carcinomas broncopulmonares no microcíticos (CBPNM) representan el 85 % de todos los casos de cáncer de pulmón. Sin embargo, la estrategia de tratamiento actual se basa principalmente en el sistema de estadificación de la operabilidad quirúrgica, que no proporciona un pronóstico preciso. La heterogeneidad entre pacientes y tumores representa un importante reto clínico. La empresa Theragnostic, de los Países Bajos, ha desarrollado una novedosa tecnología que permite estratificar a los pacientes utilizando biomarcadores de imagen e imágenes rutinarias de tomografía computarizada y tomografía por emisión de positrones. El proyecto RAIL, financiado con fondos europeos, tiene como objetivo validar un biomarcador de imagen de nivel I multisitio y su aplicación para proporcionar información pronóstica más precisa. Esto permitirá personalizar el tratamiento de los pacientes con CBPNM.
Objetivo
Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually. It also places the highest economic burden of all cancers on the EU with EUR 18.8 billion. Non-small cell lung cancer (NSCLC) comprises 85% of all lung cancer cases. The current clinical routine to guide treatment for NSCLC patients is primarily based on the TNM staging system founded in 1958, mainly to look at surgical operability. However, TNM-based evaluation, nor doctors prediction do not provide an accurate prognosis. The heterogeneity between patients (inter-patient), tumours (inter-tumour) and even within one tumour (intra-tumour) underlies these highly variable prognosis and presents a major clinical challenge.
There is a lack of easy to perform, ‘actionable’ biomarkers to stratify NSCLC patients which results in i) under-treatment in 20% of NSCLC patients leading to disease progression and ultimately death, ii) over-treatment in 30% of NSCLC patients which reduces the quality of life of patients and places an economic burden on the healthcare system and iii) ineffective clinical trial design, due to lack of optimal stratification, which requires very large, costly clinical trials to be performed in order to bring new therapeutic strategies to the market.
ptTheragnostic has developed breakthrough technology, called “Radiomics”, which was recently published in Nature Communications, which enables patient stratification through the use of imaging biomarkers acquired from routine CT & PET imaging (see animation on www.pttheragnostic.com). In Radiomics for lung cancer (RAIL) we will validate and qualify a multi-site level I imaging biomarker together with a ready-to-use application to deliver more accurate prognostic information, personalise treatment for NSCLC patients, reduce healthcare costs by EUR 500+ million and enable efficient clinical trial design.
Ámbito científico
- natural sciencescomputer and information sciencessoftware
- medical and health sciencesclinical medicineoncologylung cancer
- medical and health sciencesclinical medicineradiologynuclear medicine
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
Programa(s)
Tema(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-2-2014
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
6229 EV Maastricht
Países Bajos
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.